Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer:systematic review by Hooper, Lee et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risks and benefits of omega 3 fats for mortality, cardiovascular
disease, and cancer
Citation for published version:
Hooper, L, Thompson, RL, Harrison, RA, Summerbell, CD, Ness, AR, Moore, HJ, Worthington, HV,
Durrington, PN, Higgins, JPT, Capps, NE, Riemersma, RA, Ebrahim, SBJ & Davey Smith, G 2006, 'Risks
and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review' BMJ, vol.
332, no. 7544, pp. 752-60. DOI: 10.1136/bmj.38755.366331.2F
Digital Object Identifier (DOI):
10.1136/bmj.38755.366331.2F
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
BMJ
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Research
Risks and benefits of omega 3 fats for mortality, cardiovascular
disease, and cancer: systematic review
Lee Hooper, Rachel L Thompson, Roger A Harrison, Carolyn D Summerbell, Andy R Ness, Helen J Moore,
Helen V Worthington, Paul N Durrington, Julian P T Higgins, Nigel E Capps, Rudolph A Riemersma,
Shah B J Ebrahim, George Davey Smith
Abstract
Objective To review systematically the evidence for an effect of
long chain and shorter chain omega 3 fatty acids on total
mortality, cardiovascular events, and cancer.
Data sources Electronic databases searched to February 2002;
authors contacted and bibliographies of randomised controlled
trials (RCTs) checked to locate studies.
Review methods Review of RCTs of omega 3 intake for ≥ 6
months in adults (with or without risk factors for cardiovascular
disease) with data on a relevant outcome. Cohort studies that
estimated omega 3 intake and related this to clinical outcome
during at least 6 months were also included. Application of
inclusion criteria, data extraction, and quality assessments were
performed independently in duplicate.
Results Of 15 159 titles and abstracts assessed, 48 RCTs
(36 913 participants) and 41 cohort studies were analysed. The
trial results were inconsistent. The pooled estimate showed no
strong evidence of reduced risk of total mortality (relative risk
0.87, 95% confidence interval 0.73 to 1.03) or combined
cardiovascular events (0.95, 0.82 to 1.12) in participants taking
additional omega 3 fats. The few studies at low risk of bias were
more consistent, but they showed no effect of omega 3 on total
mortality (0.98, 0.70 to 1.36) or cardiovascular events (1.09, 0.87
to 1.37). When data from the subgroup of studies of long chain
omega 3 fats were analysed separately, total mortality (0.86, 0.70
to 1.04; 138 events) and cardiovascular events (0.93, 0.79 to
1.11) were not clearly reduced. Neither RCTs nor cohort studies
suggested increased risk of cancer with a higher intake of
omega 3 (trials: 1.07, 0.88 to 1.30; cohort studies: 1.02, 0.87 to
1.19), but clinically important harm could not be excluded.
Conclusion Long chain and shorter chain omega 3 fats do not
have a clear effect on total mortality, combined cardiovascular
events, or cancer.
Introduction
Consumption of long chain omega 3 fatty acids (eicosapentae-
noic acid (EPA), docosapentaenoic acid (DPA), and docosahexae-
noic acid (DHA)) found in fatty fish and fish oils has been linked
to the low incidence of coronary heart disease in the Inuit peo-
ple of Greenland1;  linolenic acid (ALA), a shorter chain omega
3 found in some plant oils (and variably converted to eicosapen-
taenoic acid and docosahexaenoic acid) may also be protective.2
Omega 3 fats may protect against cardiovascular disease by low-
ering blood pressure and heart rate; reducing serum
triglycerides, thrombotic tendency, inflammation, and arrhyth-
mias; and improving endothelial function, insulin sensitivity,
paraoxonase concentrations, and plaque stability.3–6
Toxic compounds, such as fat soluble methylmercury,
dioxins, and polychlorinated biphenyls, are also found in oily fish
and fish oils, but any harm from these compounds would be seen
only after long term supplementation.7 8 Animal intervention
studies and studies of adults after severe inadvertent exposure
indicate that dioxins and polychlorinated biphenyls increase the
risk of cancer.9 10 Methylmercury may increase the risk of
myocardial infarction and cause neurological damage.11 12
Since a meta-analysis of the effect of omega 3 fats on cardio-
vascular morbidity and mortality in coronary heart disease sug-
gested important benefits,13 a large intervention study has been
published.14 Our meta-analysis included these new data,
balanced protective effects with possible harm, assessed the
effects of plant based omega 3 fats on health, included people
without established cardiovascular disease, and highlighted
important questions about the role of omega 3 fats on cardiovas-
cular disease and mortality. We systematically reviewed the
effects of long chain and short chain omega 3 fats (together and
separately) on mortality, cardiovascular disease, cancer, and
bleeding events and analysed all relevant randomised controlled
trials (RCTs) and prospective cohort studies.
Methods
The study methods have been described in detail elsewhere.15
Search strategy and study selection
We searched the Cochrane Library, Medline, Embase, the
National Research Register, and SIGLE (to February 2002); we
checked the bibliographies of included studies and contacted the
authors. Articles not in English were translated. We excluded tri-
als if they were not randomised; they had no omega 3 arm; the
participants were children or were critically ill; the duration was
< 6 months; the intervention was multifactorial; or data on
death, cardiovascular disease, or cancer were not available. We
rejected cohort studies if they did not assess the intake of omega
3, follow-up was < 6 months, or the association between the
intake of omega 3 and health was not investigated. Two reviewers
assessed the inclusion of articles independently, and we
contacted authors for more information on methodological
quality, outcomes, and further studies.
A complete set of references is available on bmj.com
Cite this article as: BMJ, doi:10.1136/bmj.38755.366331.2F (published 24 March 2006)
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Data extraction and quality assessment
Two reviewers independently extracted the data and assessed the
quality of the studies. For RCTs we assessed the following quality
characteristics: concealment of allocation to the study arms and
the masking of participants, providers, and outcome assessors. We
classed trials as having low risk of bias if allocation to the study
arms was concealed and participants, providers, and outcome
assessors were masked. Quality assessment of cohort studies was
based on control group type, number lost to follow-up, baseline
similarity, adjustment for dissimilarities, and masking.
Data synthesis
For RCTs we extracted the numbers of participants experiencing
each outcome and total numbers randomised for each study
arm, and combined by using relative risks in random effects
meta-analysis.16 For cohort studies we used relative risk or odds
ratio that had been adjusted for the most confounding factors,
and we compared the most exposed quantile with the least
exposed quantile. We used one analysis only for each cohort per
outcome.
We used subgrouping of RCTs to explore the effects on mor-
tality, cardiovascular events, and cancer of long chain versus
short chain omega 3 fats and dietary advice versus supplementa-
tion. We used random effects meta-regression to analyse the
effects of the dose of omega 3 and the duration of the trial. Sen-
sitivity analyses assessed the robustness of RCT results to trial
quality by restricting the analysis to studies with low risk of bias.
We used Cochran’s test for heterogeneity to determine
whether studies in a meta-analysis evaluated the same
underlying sizes of effect. We used I2 to measure the degree of
inconsistency among studies (the proportion of total observed
variability due to genuine variation rather than random error
within studies).17
Results
We screened 15 159 titles and collected 926 full text papers.
Forty eight randomised controlled trials and 41 analyses of 26
Titles and abstracts retrieved from electronic,
bibliographical, and expert searches (n=15 159)
Titles and abstracts that were unlikely
to be relevant, excluded (n=14 233)
Papers that could not be traced (incorrect
references or not held by British Library) (n=25)
Potential RCTs pending (as presence or
absence of outcomes unknown) (n=14)
Titles and abstracts that were potentially
relevant, ordered as full text papers (n=926)
Full papers assessed for inclusion
or exclusion in duplicate (n=437)
Studies included in the review
 RCTs: 111 papers, 48 studies
 Cohort studies: 42 papers, 41 studies
Full papers quickly excluded on visual
 inspection (not duplicated)
  Potential cohort studies (n=93)
  Potential RCTs (n=371)
Potential RCTs excluded:
 Not randomised (n=21)
 No control group (n=15)
 No omega 3 arm (n=13)
 Multifactorial intervention (n=22)
 Not adult, human, well (n=25)
 Not 6 months of follow-up (n=24)
 Total (n=120)
Potential cohorts excluded:
 Not a cohort (n=10)
 No omega 3 assessment (n=108)
 No clinical outcomes (n=21)
 Not 6 months follow up (n=6)
 Omega 3 not assessed against clinical events
  (n=4)
 Or in different individuals (n=1)
 Total (n=150)
Fig 1 The selection process for randomised controlled trials (RCTs) and cohort studies on omega 3 fatty acid and health outcomes
Table 1 Characteristics of trials and cohort studies on effects of omega 3
fats on mortality, cardiovascular disease (CVD), and cancer
Criteria
Randomised
controlled trials Cohorts
Studies and participants
No of participants 36 913 563 218, plus two where the sizenot described
No of studies 48 47 published analyses from 26
No of large studies 8 (>500 participants) 10 (>20 000 participants)
Follow-up 0.5 to >z6 years 4 to 25 years
Risk of CVD
Have CVD 21 2
Moderate risk 10 2
Low risk 17 22
Sex
≥70% men 24 14
31% to 69% men 17 4
≤30% men 5 7
Not stated 2 1
Main outcome*
CVD or mortality 32 13
Cancer 0 10
Other outcomes 16 10
*Several cohorts appear to have more than one main outcome.
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cohort studies fulfilled all inclusion criteria (fig 1; for a complete
set of references see bmj.com). Table 1 shows the main
characteristics of the included studies.
Intervention or exposure
Dietary supplements were given in 44 trials (36 as capsules, six as
oil, one each as liquid emulsion and enriched margarine), advice
on eating oily fish in three, and advice on diet and food supple-
ments in one. Supplements were long chain omega 3 fats
(usually whole or concentrated fish oil; one small trial used
refined eicosapentaenoic acid and one used refined docosahex-
aenoic acid), and five studies provided shorter chain omega 3
fats. Doses of long chain omega 3 fats (summing eicosapentae-
noic acid, docosahexaenoic acid, and docosapentaenoic acid)
varied from 0.4 g to 7.0 g per day. Control groups received veg-
etable oils, other fats, “inert” or ill defined substances, different
dietary advice, or nothing. The intervention lasted 6-11 months
Table 2 Quality assessment of randomised controlled trials of the effect of omega 3 fats on mortality, cardiovascular disease, and cancer
Study Concealment ofallocation
Masking
Dropouts for analysis of events (intervention,
control) Summary risk of bias
Participants
Providers of
care
Assessors of
outcome
Almallah 1998w1 Done Yes Yes Yes ?/18, ?/18 Low
Bairati 1992w2 Done Yes Yes Yes 48/107, 38/98 Low
Bellamy 1992*w3 Unclear Unclear Unclear Unclear 3/60, 7/60 Medium or high
Belluzzi 1996w4 Done Yes Yes Yes 5/39, 2/39 Low
Bemelmans 2002w5 Done Yes Yes Yes ?/51, ?/52 Low
Bonnema 1995w6 Done Yes Yes Yes 0/14, 1/14 Low
Borchgrevink 1966w7 Done Yes Yes Yes ?/100, ?/100 Low
Brox 2001w8 Unclear No Yes Yes Seal oil 8/40, cod liver oil 2/40, 1/40 Medium or high
Burr (DART) 1989w9 Unclear No No Yes 0/1015, 0/1018 for mortality Medium or high
Burr 2003w10 Unclear No No Yes 0/1571, 0/1543 for mortality Medium or high
Connor 1993w11 Done Yes Yes Yes ?/8, ?/8 Low
Dehmer 1998w12 Not done No No No 3/46, 5/44 Medium or high
Dry 1991w13 Done Yes Yes Yes 0/6, 0/6 Low
Eritsland 1996w14 Done No No Yes 15/317, 14/293 Medium or high
Franzen 1993w15 Unclear Yes Unclear Yes 0/15, 0/15 Medium or high
Geusens 1994*w16 Unclear Yes Yes Yes Low dose 9/30, high dose 11/30, 10/30 Medium or high
GISSI-P 1999*w17 Done No Unclear Yes ?/5665, ?/5658 Medium or high
Greenfield 1993w18 Done Yes Yes Yes 3/16, 1/8 Low
Hawthorne 1992w19 Done Unclear Yes Yes 5/49, 6/47 Medium or high
Johansen 1999*w20 Unclear Yes Yes Yes 54/250, 58/250 Medium or high
Katan 1997w21 Done No Unclear Yes Low dose ?/15, med dose ?/15, high dose
?/14, ?/14
Medium or high
Kaul 1992w22 Unclear No No Yes ?/58, ?/49 Medium or high
Lau 1993w23 Done Yes Yes Yes 9/32, 16/32 Low
Lau 1995w24 Done Yes Yes Yes 0/25, 0/20 Low
Leaf 1994w25 Done Yes Yes Yes 69/275, 69/276 Low
Loeschke 1996w26 Done Yes Yes Yes 0/31, 0/33 Low
Lorenz-Meyer 1996w27 Done Yes Yes Yes ?/70, ?/65 Low
Malaguarnera 1999*w28 Unclear No Unclear Unclear ?/26, ?/26 Medium or high
Maresta 2002w29 Done Yes Yes Yes 44/169, 38/170 Low
Mate-Jimenez 1991w30 Done No Yes Yes 4/19, 6/19 Medium or high
Milner 1989w31 Done No Unclear Yes 0/100, 0/100 Medium or high
Natvig 1968*w32 Done Yes Yes Yes 2/6716, 2/6690 Low
Nilsen 2001w33 Done Yes Yes Yes ?/150, ?/150 Low
Nye 1990*w34 Unclear Yes Yes Yes 0/36, 0/37 Medium or high
Reis 1991w35 Done Yes Yes Yes 22/146, 10/72 Low
Rossing 1996w36 Done Yes Yes Yes 0/18, 0/18 Low
Sacks (HARP) 1995*w37 Unclear Yes Yes Yes 10/41, 11/39 Medium or high
Sacks (TOHP 1) 1994*w38 Done Yes Yes Yes 1/175, 1/175 Low
Sarkkinen 1998w39 Unclear No No Yes 0/41, 0/37 Medium or high
Selvais 1995w40 Done Yes Yes Yes 4/12, 2/12 Low
Shimizu 1995w41 Not done No No Yes ?/29, ?/16 Medium or high
Singh 1997†w42 Done No Yes Yes Fish oil 4/122, mustard oil 8/120, 6/118 Medium or high
Sirtori 1998w43 Done Yes Yes Yes 28/470, 39/465 Low
Skoldstam 1992w44 Done No No No 1/23, 2/23 Medium or high
Terano 1999w45 Done No No Yes 0/10, 0/10 Medium or high
Thien 1993w46 Done Yes Yes Yes 6/21, 6/16 Low
Veale 1994w47 Done Yes Yes Yes 4/19, 0/19 Low
von Schacky 1999w48 Done Yes Yes Yes ?/112, ?/111 Low
Allocation concealment was coded as done, unclear, or not done; blinding of participants, providers, and outcome assessors was coded as yes (where there was a clear and realistic attempt to
blind—success of blinding was rarely checked in the studies), unclear, or no (in consultation with authors of trials where possible).
A trial was considered to be at low risk of bias if allocation concealment was “done” and blinding of participants, providers, and outcome assessors was coded “yes.” All other trials were
considered at moderate or high risk of bias.
*Did not respond to our request for further information on the quality of their studies or provide additional data on trial outcomes.
†The BMJ has concerns about the validity of another paper written by this author.18
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in 23 studies, 12-23 months in 16, 24-47 months in eight, and
≥ 48 months in one study.
Intake of omega 3 (varying combinations of eicosapentae-
noic acid, docosahexaenoic acid, docosapentaenoic acid, along
with  linolenic acid, supplemental fish oils, or dietary oily fish)
was assessed by dietary and biochemical means in two cohorts,
dietary means only in 18, and biochemical means only in 10.
Groups with the lowest and highest intake of long chain omega
3 differed by 0.1-0.6 g omega 3 per day.
Methodological quality
Twenty five RCTs were rated as having a low risk of bias (table 2).
Losses to follow-up were unclear in 16 cohort studies. In 15
cohort studies the outcome assessors were blinded to exposure,
in two they were not blinded, and in nine blinding was unclear.
In the seven cohort studies that described omega 3 intake at
baseline (five assessed long chain omega 3 fats only, one short
chain omega 3 fats only, and one assessed both), the characteris-
tics of participants with high and low intake of omega 3 fats dif-
fered. People who consumed most long chain omega 3 at
baseline had an advantage with regard to lifestyle (smoking, diet,
and exercise), interest in health, and social factors (education, liv-
ing in town). Adjustment for these potential confounding factors
may not have been adequate (table 3).
Total mortality
Deaths occurred in 15 RCTs (1995 deaths), and authors of 29
RCTs reported that no deaths occurred. Evidence that risk of
death was reduced in participants randomised to omega 3 (rela-
tive risk 0.87, 95% confidence interval 0.73 to 1.03) was weak, and
inconsistency was moderate (I2 = 42%) (fig 2). When analysis was
restricted to studies at low risk of bias this effect was attenuated
(0.98, 0.70 to 1.36; 138 deaths), and inconsistency between RCTs
was low (I2 = 0%). This sensitivity analysis removed the RCT by
Singh, whose studies have been questioned.18
Results were similar for long chain versus short chain omega
3 (fig 2) and dietary advice versus supplements (data not shown).
Meta-regression indicated that the risk of death increased as the
length of the RCT increased (regression coefficient 0.008, 0.003
to 0.012). This is compatible with omega 3 fats having an early
protective effect that later becomes harmful; however, the
association was lost when we removed the large trial by Burr et
al.14 Meta-regression did not suggest a relation between mortality
and the dose of long chain omega 3. Cohort studies suggested
that omega 3 protected against death (0.65, 0.48 to 0.88;
I2 = 36%), but it was unclear whether adjustment for confounders
was adequate.
Combined cardiovascular events
Eighteen RCTs provided data on cardiovascular events in 2628
participants. The meta-analysis showed no definite effect of
omega 3 fats on cardiovascular events, but confidence intervals
were wide (0.95, 0.82 to 1.12) and inconsistency was high
(I2 = 65%) (fig 3). Removing studies at moderate or high risk of
bias reduced but did not remove inconsistency (1.09, 0.87 to
1.37; 570 events; I2 = 49%).
Subgrouping by long chain versus short chain omega 3 or by
advice to eat oily fish versus supplements did not generate robust
effects of omega 3 fats on cardiovascular events. Cohort studies
provided no strong evidence that omega 3 fats protect against
cardiovascular events.
Cancer
Ten RCTs reported the incidence of cancer; 391 diagnoses of
cancer or death from cancer occurred in 17 433 participants
(two of the trials reported no cancers). We found no evidence
that omega 3 fats had an effect on the incidence of cancer (1.07,
0.88 to 1.30) and there was no inconsistency (I2 = 0%) (fig 4). Five
trials and seven events remained on sensitivity analysis.
Seven cohort studies provided data on cancer (832 events in
the highest and lowest quantiles), and meta-analysis found no
effect of high versus low intake of omega 3 (1.02, 0.87 to 1.19;
I2 = 21%).
Outcomes related to bleeding
Nine RCTs reported at least one stroke (243 strokes in total), but
little information was available specifically on haemorrhagic
stroke. Omega 3 had no clear effect on the total numbers of
strokes (1.17, 0.91 to 1.51; I2 = 0%), in sensitivity analysis (29
events), or in four cohort studies (0.87, 0.72 to 1.04) (fig 5).
Discussion
Our meta-analysis of RCTs assessing the effects of increased
omega 3 fats on total mortality found substantial variations
between studies. Studies with stronger methodology had more
consistent results, and the pooled relative risk of these studies
was 0.98 (0.70 to 1.36; 138 events). We found no evidence from
RCTs or cohort studies that omega 3 fats have an effect on com-
bined cardiovascular events. Neither RCTs nor cohort studies
showed significantly increased risks of cancer or stroke with
higher intake of omega 3, but there were too few events to rule
out important effects.
Table 3 Adjustment carried out in 10 cohorts that assessed effects of
omega 3 fats on cancer
Factors* No of cohorts adjusted†
Lifestyle factors
Smoking 2
Alcohol intake 2
Physical activity 1
Dietary fibre intake 1
Saturated fat intake 1
Trans fat intake 0
Red meat intake 2
Fruit intake 0
Vegetable intake 0
Others‡:
Body mass index 4
Total energy intake 5
Other dietary factors, height, parity, and menopausal
status
1 each
Social factors
Place of residence 2
Education 2
Other‡:
Ethnic origin 1
Socioeconomic status 1
Interest in health
Vitamin E supplementation 0
Multivitamin supplementation 0
Others‡:
Use of hormone replacement therapy 1
Family history of the disease studied 2
Precancerous symptoms 1
*Factors that differ consistently between people taking most and least fish based omega 3
fats; the association was consistent across all cohorts that assessed it and was seen in at
least two cohorts.
†The number of cohorts that adjusted for the factor in the most adjusted analysis, of the 10
cohorts used in the cancer outcomes analysis. Six cohorts also adjusted for age.
‡Unclear if consistently associated with omega 3 fats.
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RCT data
 Borchgrevink 1966
 Natvig 1968
 Burr (DART) 1989
 Kaul 1992
 Leaf 1994
 Sacks (HARP) 1995
 Eritsland 1996
 Singh 1997
 GISSI-P 1999
 Johansen 1999A
 von Schacky 1999
 Brox 2001
 Nilsen 2001
 Bemelmans 2002
 Burr 2003
Subtotal (95% CI)
Total events: 960 (high omega 3 fats), 1035 (low omega 3/control)
Test for heterogeneity: χ2=24.12, df=14, P=0.04, I 2=42.0%
Test for overall effect: z=1.58, P=0.11
RCT data, sensitivity analysis
 Borchgrevink 1966
 Natvig 1968
 Leaf 1994
 von Schacky 1999
 Nilsen 2001
 Bemelmans 2002
Subtotal (95% CI)
Total events: 68 (high omega 3 fats), 70 (low omega 3/control)
Test for heterogeneity: χ2=3.86, df=5, P=0.57, I 2=0%
Test for overall effect: z=0.14, P=0.89
RCT data, marine omega 3 fats only
 Burr (DART) 1989
 Kaul 1992
 Leaf 1994
 Sacks (HARP) 1995
 Eritsland 1996
 Singh 1997
 GISSI-P 1999
 Johansen 1999A
 von Schacky 1999
 Brox 2001
 Nilsen 2001
 Burr 2003
Subtotal (95% CI)
Total events: 888 (high omega 3 fats), 967 (low omega 3/control)
Test for heterogeneity: χ2=19.98, df=11, P=0.05, I 2=44.9%
Test for overall effect: z=1.542, P=0.12
RCT data, α linolenic acid only
 Borchgrevink 1966
 Natvig 1968
 Singh 1997
 Bemelmans 2002
Subtotal (95% CI)
Total events: 72 (high omega 3 fats), 58 (low omega 3/control)
Test for heterogeneity: χ2=4.27, df=3, P=0.23, I 2=29.8%
Test for overall effect: z=0.62, P=0.54
Cohort data
 Dolecek 1991
 Erkkila 2003
 Hu 2003
Subtotal (95% CI)
Total events: 126 (high omega 3 fats), 192 (low omega 3/control)
Test for heterogeneity: χ2=3.13, df=2, P=0.21, I 2=36.1%
Test for overall effect: z=2.81, P=0.005
0.1 0.2 0.5 1 2 5 10
Study or subcategory
10/100
43/6716
93/1015
0/58
0/275
0/41
8/317
30/242
477/5665
1/250
1/112
0/80
11/150
3/109
283/1571
16 701
10/100
43/6716
0/275
1/112
11/150
3/109
7462
93/1015
0/58
0/275
0/41
8/317
14/122
477/5665
1/250
1/112
0/80
11/150
283/1571
9656
10/100
43/6716
16/120
3/109
7045
72/1251
5/132
49/491
1874
High omega 3 fat
(n/N)
14/100
40/6690
131/1018
1/49
2/276
1/39
6/293
26/118
554/5658
3/250
2/111
1/40
11/150
1/157
242/1543
16 492
14/100
40/6690
2/276
2/111
11/150
1/157
7484
131/1018
1/49
2/276
1/39
6/293
13/59
554/5658
3/250
2/111
1/40
11/150
242/1543
9486
14/100
40/6690
13/59
1/157
7006
99/1307
16/133
77/487
1927
Low omega 3/control
(n/N)
Relative risk
(random) (95% CI)
0.71 (0.33 to 1.53)
1.07 (0.70 to 1.64)
0.71 (0.55 to 0.92)
0.28 (0.01 to 6.78)
0.20 (0.01 to 4.16)
0.32 (0.01 to 7.57)
1.23 (0.43 to 3.51)
0.56 (0.35 to 0.91)
0.86 (0.77 to 0.97)
0.33 (0.03 to 3.18)
0.50 (0.05 to 5.39)
0.17 (0.01 to 4.05)
1.00 (0.45 to 2.24)
4.32 (0.46 to 41.00)
1.15 (0.98 to 1.34)
0.87 (0.73 to 1.03)
0.71 (0.33 to 1.53)
1.07 (0.70 to 1.64)
0.20 (0.01 to 4.16)
0.50 (0.05 to 5.39)
1.00 (0.45 to 2.24)
4.32 (0.46 to 41.00)
0.98 (0.70 to 1.36)
0.71 (0.55 to 0.92)
0.28 (0.01 to 6.78)
0.20 (0.01 to 4.16)
0.32 (0.01 to 7.57)
1.23 (0.43 to 3.51)
0.52 (0.26 to 1.04)
0.86 (0.77 to 0.97)
0.33 (0.03 to 3.18)
0.50 (0.05 to 5.39)
0.17 (0.01 to 4.05)
1.00 (0.45 to 2.24)
1.15 (0.98 to 1.34)
0.86 (0.70 to 1.04)
0.71 (0.33 to 1.53)
1.07 (0.70 to 1.64)
0.61 (0.31 to 1.17)
4.32 (0.46 to 41.00)
0.87 (0.57 to 1.34)
0.76 (0.57 to 1.02)
0.31 (0.12 to 0.83)
0.63 (0.45 to 0.88)
0.65 (0.48 to 0.88)
Relative risk
(random) (95% CI)
Favours high
omega 3
Favours low
omega 3
Fig 2 Effect of omega 3 fatty acids on mortality. For references see bmj.com
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Strengths and weaknesses
The largest studies reviewed had greater potential for bias than
some of the smaller ones. We hoped that pooling studies at low
risk of bias might provide enough power to inform us of effects
on health, but this was not the case (only 138 deaths and 570
cardiovascular events). Similarly, analysis of the effects of omega
3 on rarer outcomes such as stroke had insufficient power to
detect clinically important effects. Unlike previous meta-
analyses, we reviewed systematically the effects of omega 3 fats
on mortality, cardiovascular disease, cancer, and bleeding events
and analysed all relevant RCTs and prospective cohort studies.
We also accounted for differences in study quality and examined
the effects of long chain and short chain omega 3 fats in a wide
group of participants; this provides high quality evidence to
guide policy and practice.
Other studies
Our findings differ from those of a recent systematic review by
Bucher et al,13 which reviewed trials assessing the effects of long
chain omega 3 fats over at least six months in patients with coro-
nary heart disease and found significant protection frommortal-
ity (0.8, 0.7 to 0.9) and sudden death (0.7, 0.6 to 0.9). Bucher et al
analysed 11 RCTs (nine included here, two excluded as multifac-
torial interventions) with 15 806 participants and 1335 deaths
but did not include the recent study by Burr et al with 3114 par-
ticipants included in our study.14
RCT data
 Borchgrevink 1966
 Natvig 1968
 Burr (DART) 1989
 Reis 1991
 Kaul 1992
 Leaf 1994
 Sacks (HARP) 1995
 Eritsland 1996
 Singh 1997
 Dehmer 1998
 GISSI-P 1999
 Johansen 1999A
 Malaguarnera 1999
 von Schacky 1999
 Brox 2001
 Nilsen 2001
 Maresta 2002
 Burr 2003
Subtotal (95% CI)
Total events: 1334 (high omega 3 fats), 1294 (low omega 3/control)
Test for heterogeneity: χ2=49.01, df=17, P<0.0001, I 2=65.3%
Test for overall effect: z=0.58, P=0.57
RCT data, sensitivity analysis
 Borchgrevink 1966
 Natvig 1968
 Reis 1991
 Leaf 1994
 von Schacky 1999
 Nilsen 2001
 Maresta 2002
Subtotal (95% CI)
Total events: 320 (high omega 3 fats), 250 (low omega 3/control)
Test for heterogeneity: χ2=11.69, df=6, P=0.07, I 2=48.7%
Test for overall effect: z=0.75, P=0.46
Cohort data
 Ascherio 1995
 Morris 1995
 Pietinen 1997
 Rissanen 2000
 Oomen 2001
 Hu 2002
 Erkkila 2003
Subtotal (95% CI)
Total events: 902 (high omega 3 fats), 1027 (low omega 3/control)
Test for heterogeneity: χ2=28.09, df=6, P<0.0001, I 2=78.6%
Test for overall effect: z=0.84, P=0.40
Note: Borchgrevink 1966, Natvig 1968, and 120 participants from Singh 1997 received short chain (not long chain) omega 3 fats.
Trials of long chain omega 3 fats only had a pooled relative risk of cardiovascular events of 0.93 (95% CI 0.79 to 1.11), and trials of short chain omega 3 only
had a pooled relative risk of 0.92 (0.58 to 1.45)
Study or subcategory
20/100
99/6716
127/1015
93/146
25/58
3/275
7/41
15/317
64/242
13/46
556/5665
1/250
0/26
17/112
0/80
72/150
16/169
206/1571
16 979
20/100
99/6716
93/146
3/275
17/112
72/150
16/169
7668
299/8481
97/3950
247/4386
31/374
35/222
182/16 791
11/132
34 336
High omega 3 fat
(n/N)
17/100
87/6690
149/1018
29/72
18/48
8/276
7/39
12/293
56/118
21/44
621/5658
3/250
1/26
26/111
1/40
69/150
14/170
155/1543
16 646
17/100
87/6690
29/72
8/276
26/111
69/150
14/170
7569
294/9329
97/4335
284/4386
56/374
21/222
261/16 587
14/133
35 366
Low omega 3/control
(n/N)
Relative risk
(random) (95% CI)
1.18 (0.66 to 2.11)
1.13 (0.85 to 1.51)
0.85 (0.69 to 1.07)
1.58 (1.16 to 2.15)
1.15 (0.72 to 1.84)
0.38 (0.10 to 1.40)
0.95 (0.37 to 2.46)
1.16 (0.55 to 2.43)
0.56 (0.42 to 0.74)
0.59 (0.34 to 1.03)
0.89 (0.80 to 1.00)
0.33 (0.03 to 3.18)
0.33 (0.01 to 7.82)
0.65 (0.37 to 1.13)
0.17 (0.01 to 4.05)
1.04 (0.82 to 1.33)
1.15 (0.58 to 2.28)
1.31 (1.07 to 1.59)
0.95 (0.82 to 1.12)
1.18 (0.66 to 2.11)
1.13 (0.85 to 1.51)
1.58 (1.16 to 2.15)
0.38 (0.10 to 1.40)
0.65 (0.37 to 1.13)
1.04 (0.82 to 1.33)
1.15 (0.58 to 2.28)
1.09 (0.87 to 1.37)
1.12 (0.95 to 1.31)
1.10 (0.83 to 1.45)
0.87 (0.74 to 1.03)
0.55 (0.37 to 0.84)
1.67 (1.00 to 2.77)
0.69 (0.57 to 0.83)
0.79 (0.37 to 1.68)
0.91 (0.73 to 1.13)
Relative risk
(random) (95% CI)
0.1 0.2 0.5 1 2 5 10
Favours high
omega 3
Favours low
omega 3
Fig 3 Effect of omega 3 fatty acids on cardiovascular events. For references see bmj.com
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A systematic review from the United States collated RCTs
and cohort studies to assess the effects of marine omega 3 fats,
but this study did not performmeta-analysis, reported the results
of the largest studies only, and did not investigate reasons for
conflicting results.19 A recent review from the United Kingdom of
the benefits and risks of consumption of fish on cardiovascular
RCT data
 Borchgrevink 1966
 Burr (DART) 1989
 Loeschke 1996
 Rossing 1996
 GISSI-P 1999
 Terano 1999
 von Schacky 1999
 Brox 2001
 Nilsen 2001
 Burr 2003
Subtotal (95% CI)
Total events: 203 (high omega 3 fats), 188 (low omega 3/control)
Test for heterogeneity: χ2=2.69, df=7, P=0.91, I 2=0%
Test for overall effect: z=0.69, P=0.49
Cohort data
 Dolecek 1991
 Giovannucci 1993
 Harvei 1997
 Kato 1997
 Veierod 1997B
 Schuurman 1999
 Terry 2001
Subtotal (95% CI)
Total events: 420 (high omega 3 fats), 412 (low omega 3/control)
Test for heterogeneity: χ2=7.55, df=6, P=0.27, I 2=20.5%
Test for overall effect: z=0.20, P=0.84
Study or subcategory
0/100
6/1015
0/31
1/18
142/5665
0/10
1/112
0/80
2/150
51/1571
8752
26/1251
20/8197
35/106
18/3682
79/28 078
126/1790
116/15 366
58 470
High omega 3 fat
(n/N)
1/100
4/1018
1/33
0/18
134/5658
0/10
1/111
0/40
0/150
47/1543
8681
28/1307
22/8072
33/106
29/3682
44/23 533
135/1918
121/15 366
53 984
Low omega 3/control
(n/N)
Relative risk
(random) (95% CI)
0.33 (0.01 to 8.09)
1.50 (0.43 to 5.32)
0.35 (0.01 to 8.38)
3.00 (0.13 to 69.09)
1.06 (0.84 to 1.34)
Not estimable
0.99 (0.06 to 15.65)
Not estimable
5.00 (0.24 to 103.28)
1.07 (0.72 to 1.57)
1.07 (0.88 to 1.30)
0.97 (0.57 to 1.65)
0.90 (0.49 to 1.64)
1.06 (0.72 to 1.57)
0.62 (0.35 to 1.12)
1.50 (1.04 to 2.17)
1.00 (0.79 to 1.26)
0.96 (0.74 to 1.24)
1.02 (0.87 to 1.19)
Relative risk
(random) (95% CI)
0.1 0.2 0.5 1 2 5 10
Favours high
omega 3
Favours low
omega 3
Note: Participants in Borchgrevink 1966 received short chain omega 3 fats (the remaining trials provided long chain omega 3 fats).
Trials of long chain omega 3 fats only had a pooled relative risk of cancer of 1.08 (95% CI 0.88 to 1.31)
Fig 4 Effect of omega 3 fatty acids on the diagnosis of cancer or death from cancer. For references see bmj.com
RCT data
 Borchgrevink 1966
 Natvig 1968
 Burr (DART) 1989
 Sacks (HARP) 1995
 Eritsland 1996
 GISSI-P 1999
 von Schacky 1999
 Bemelmans 2002
 Burr 2003
Subtotal (95% CI)
Total events: 131 (high omega 3 fats), 112 (low omega 3/control)
Test for heterogeneity: χ2=4.51, df=8, P=0.81, I 2=0%
Test for overall effect: z=1.24, P=0.22
Cohort data
 Morris 1995
 Iso 2001
 Yuan 2001
 He 2002
Subtotal (95% CI)
Total events: 283 (high omega 3 fats), 319 (low omega 3/control)
Test for heterogeneity: χ2=3.56, df=3, P=0.31, I 2=15.8%
Test for overall effect: z=1.58, P=0.11
Study or subcategory
0/100
13/6716
5/1015
1/41
3/317
92/5665
1/112
0/109
16/1571
15 646
36/3950
103/15 968
85/2901
59/3628
26 447
High omega 3 fat
(n/N)
1/100
9/6690
2/1018
0/39
4/293
77/5658
3/111
2/157
14/1543
15 609
39/4335
143/15 968
106/3631
31/1645
25 579
Low omega 3/control
(n/N)
Relative risk
(random) (95% CI)
0.33 (0.01 to 8.09)
1.44 (0.62 to 3.36)
2.51 (0.49 to 12.89)
2.86 (0.12 to 68.10)
0.69 (0.16 to 3.07)
1.19 (0.88 to 1.61)
0.33 (0.03 to 3.13)
0.29 (0.01 to 5.93)
1.12 (0.55 to 2.29)
1.17 (0.91 to 1.51)
1.01 (0.65 to 1.59)
0.72 (0.56 to 0.93)
1.00 (0.76 to 1.33)
0.86 (0.56 to 1.33)
0.87 (0.72 to 1.04)
Relative risk
(random) (95% CI)
0.1 0.2 0.5 1 2 5 10
Favours high
omega 3
Favours low
omega 3
Note: Participants in Borchgrevink 1966, Natvig 1968, and Bemelmans 2002 received short chain omega 3 fats, participants in the other trials received long
chain omega 3 fats. Trials of long chain omega 3 fats only had a pooled relative risk of stroke of 1.17 (95% CI 0.90 to 1.53), and trials of short chain omega 3
fats only had a pooled relative risk of 1.18 (0.53 to 2.60)
Fig 5 Effect of omega 3 fatty acids on stroke. For references see bmj.com
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disease mentioned only four large trials and did not pool the
results.20
Our inclusion of studies with short chain omega 3 as the
active intervention or with participants who had a lower risk of
cardiovascular disease does not explain the differences between
our results and those of Bucher et al. When we pooled studies in
which participants were given only long chain omega 3 fats or
were at high risk of cardiovascular disease the risk of death was
not significantly reduced. However, when we removed the study
by Burr et al from our meta-analysis, risk of death was similar to
that reported by Bucher et al (0.83, 0.75 to 0.91). The study by
Burr et al (included in our review as an unpublished study, since
published) is the second largest study in terms of deaths reported
(525 deaths; the GISSI-P study reports 1031 deaths).21
Why does the study by Burr et al contradict the other large
studies by not suggesting a benefit of omega 3?14 The first possi-
ble explanation is that this RCT had the longest follow-up of all
RCTs and the harmful effects of methylmercury could be cumu-
lative. Time course analysis of the GISSI-P trial was consistent
with the risk of death rising over the 42 months of the trial, but
the increase in mortality was seen within the first year in the
study by Burr et al.14 22 A second explanation is that the study by
Burr et al was the only RCT that specifically enrolled men
treated for angina. Post hoc subgroup analysis of the GISSI-P
trial indicates that people with heart failure benefited most from
omega 3 supplements (R Marchioli, personal communication,
2004). As heart failure is more common after myocardial infarc-
tion this may explain an attenuation of effect but would not
explain the increase in risk suggested in the study by Burr et al. A
third possibility is that omega 3 from oily fish has a different
effect to fish oil supplements, but this was investigated by Burr et
al and found not to explain the differences. It is therefore not
clear why the results of Burr et al differ from the other large
studies on fish based omega 3. It is possible that performance
bias due to differential care in the intervention and control arms
occurred in trials where the intervention was not masked, includ-
ing GISSI-P and the Burr study,14 21 23 but dietary intake, other
relevant risk factors, and pharmacotherapy appeared similar in
both arms of these trials. It may be that the effect of omega 3 fats
on cardiovascular disease is smaller than previously thought, or
that its beneficial effect is limited to a specific group (such as
patients after myocardial infarction or with heart failure) not
represented in the study by Burr et al.14
Cohort studies or RCTs?
A recent meta-analysis assessed the effects of consumption of
fish on stroke in cohort studies and found that people who ate
white or oily fish at least once a week had a significantly reduced
risk of stroke.24 We excluded cohort studies that assessed only
total fish intake (as this is not clearly related to omega 3 intake).
The web of lifestyle, interest in health, and social factors (health
patterning) seen in the cohort studies included in our review
provides an advantage to people taking most long chain omega
3 fats, and this makes adequate adjustment for confounding dif-
ficult, if not impossible. Thus, we must rely on high quality RCTs
to provide non-confounded answers about the effects of omega
3 fats on health. Some effects of fish on health may be due to
components other than omega 3—for example, selenium or vita-
min D.
Interpretation
It is not clear whether long chain or short chain omega 3 fats
(together or separately) reduce or increase total mortality,
cardiovascular events, cancer, or strokes.Our findings do not rule
out an important effect of omega 3 fats on total mortality, as
robust trials at low risk of bias reported few deaths. There is no
evidence that the source (dietary or supplemental) and dose of
omega 3 fats affected the effectiveness of long chain omega 3
fats.
UK guidelines encourage the general public to eat more oily
fish, and higher amounts are advised after myocardial infarction
(supported by trials after myocardial infarction).20 25 26 This advice
should continue at present but the evidence should be reviewed
regularly. It is probably not appropriate to recommend a high
intake of omega 3 fats for people who have angina but have not
had a myocardial infarction.
Adjustment for lifestyle factors appeared to be inadequate in
the cohort studies, so policy and lifestyle decisions should be
based on data from RCTs. To understand the effects of omega 3
fats on health, we need more high quality RCTs (with adequate
concealment of allocation and masking of participants and
health providers) of long duration that also report the associated
harms.
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